Bristol-Myers Squibb reports third quarter 2012 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) posted third quarter 2012 net sales of $3.7 billion, a decrease of 30% compared to the same period a year ago, following the U.S. patent expiration of Avapro®/Avalide® in March 2012 and Plavix® in May 2012.
AstraZeneca and Ironwood announce linaclotide collaboration for China
- Details
- Category: AstraZeneca
AstraZeneca and Ironwood Pharmaceuticals, Inc. announced an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Abbott announces three-year long-term data evaluating efficacy with HUMIRA® (Adalimumab)
- Details
- Category: Abbott
Abbott announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA® (adalimumab) ULTRA 1 and ULTRA 2 studies. Adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to certain other medications and were treated with HUMIRA were evaluated for symptom improvement for up to three years.
Abbott reports double digit earnings per share growth in the third quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the third quarter ended Sept. 30, 2012. Diluted earnings per share, excluding specified items, were $1.30, reflecting 10.2 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.21, including specified items.
YERVOY® (ipilimumab) awarded prestigious Prix Galien USA 2012 for best biotechnology product
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced that YERVOY® (ipilimumab), a novel immunotherapy and the first medicine approved for unresectable or metastatic melanoma in more than a decade, received the Prix Galien USA 2012 Award for Best Biotechnology Product.
Roche Group posts strong sales growth in the third quarter
- Details
- Category: Roche
Roche sales grew 4% to 33.7 billion Swiss francs thanks to strong demand for its cancer medicines and its clinical lab business. Uptake of the Group's recently launched cancer medicines Zelboraf, Erivedge and Perjeta has been positive. The Diagnostics Division maintained its global market leadership due to strong sales to hospital and private clinical laboratories.
Boehringer Ingelheim congratulates Nobel Prize winner Prof. Brian Kobilka
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim congratulates Prof. Brian Kobilka of Stanford University, who was awarded the Nobel Prize in chemistry. Prof. Kobilka has made ground-breaking contributions to the understanding of how cells sense information from the autonomic nervous system and convert them into cellular responses.
More Pharma News ...
- UCB announces third research collaboration with Harvard University
- Millions of children in Pakistan to be protected against pneumococcal disease with GSK's Synflorix
- Sanofi and Bristol-Myers Squibb announce restructuring of alliance agreement
- ELIQUIS® (apixaban) demonstrates consistent reductions in stroke and systemic embolism, major bleeding and mortality
- Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of metastatic colorectal cancer
- Abbott's HUMIRA® (adalimumab) receives FDA approval for the treatment of ulcerative colitis
- Bayer joins global initiative for better access to safe and effective contraception